Abstract

Venous thromboembolism is a common complication in cancer patients, and thromboembolism is the second most common cause of death after cancer progression. A number of clinical practice guidelines provide recommendations for the management of cancer-associated thrombosis. However, the guidelines lack recommendations covering commonly encountered clinical challenges (for example, thrombocytopenia, recurrent venous thromboembolism, etc.) for which little or no evidence exists. Accordingly, recommendations were developed to provide expert guidance to medical oncologists and other health care professionals caring for patients with cancer-associated thrombosis. The current expert consensus was developed by a team of 21 clinical experts. For each identified clinical challenge, the literature in medline, embase, and Evidence Based Medicine Reviews was systematically reviewed. The quality of the evidence was assessed, summarized, and graded. Consensus statements were generated, and the experts voted anonymously using a modified Delphi process on their level of agreement with the various statements. Statements were progressively revised through separate voting iterations and were then finalized. Clinicians using these recommendations and suggestions should tailor patient management according to the risks and benefits of the treatment options, patient values and preferences, and local cost and resource allocations.

Highlights

  • Venous thromboembolism is a common complication in cancer patients, and thromboembolism is the second most common cause of death after cancer progression

  • Deep-vein thrombosis, pulmonary embolism, recommendations general population is increased by a factor of 41

  • In the cancer patient population, thromboembolism is associated with significant morbidity and mortality, and it is the second most common cause of death after cancer progression[2]

Read more

Summary

INTRODUCTION

General population is increased by a factor of 41. In the cancer patient population, thromboembolism is associated with significant morbidity and mortality, and it is the second most common cause of death after cancer progression[2]. A number of published clinical practice guidelines have provided recommendations to medical oncologists for the management of cancer-associated thrombosis[3,4,5]; currently available guidelines do not provide recommendations for challenging clinical situations (for example, thrombocytopenia, recurrent vte, catheter-related upper extremity dvt, etc.) encountered by health care practitioners caring for this patient population

METHODS
Sources and Searches
Grading of the Evidence and Consensus Process
RECOMMENDATION STATEMENTS
Incidental Cancer-Associated Thrombosis
Catheter-Related Cancer-Associated Thrombosis
Recurrent Cancer-Associated Thrombosis Despite Anticoagulation
Thrombocytopenia Resulting from Chemotherapy or Marrow Infiltration by Cancer
Moderate-to-Severe Renal Impairment
Findings
CONFLICT OF INTEREST DISCLOSURES

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.